|
As CTO of Oxonica, Dr. Michael Natan guides technical development of the company’s product portfolio for the diagnostics and security markets. Formerly CEO and Founder of NanoPlex Technologies, Inc., Michael has unparalleled experience in metal nanoparticle technology with more than 60 published papers and several issued patents to his name. Prior to NanoPlex, Michael served as Chief Technical Officer of SurroMed, Inc, where he led the creation and development of its integrated platform for comprehensive phenotyping and biomarker discovery.
Michael has also held positions as a full professor of chemistry at The Pennsylvania State University, and founder of Auspex Technologies, LLC, a technology holding company acquired by SurroMed. During his tenure at Penn State, he received a Beckman Young Investigator Award, a Sloan Fellowship, and research funding from NIH, NSF, DARPA/ONR, EPA and USDA. Michael received a B.S. degree in Chemistry from Yale University, a Ph.D. in Chemistry from M.I.T., and was an NIH postdoctoral fellow at Northwestern University | 